Randomized study with inclusion of certain types of immunotherapy in the schedule of complex treatment was conducted in 89 patients with kidney carcinoma after the operation. In 63 patients the tumor was in stage T3N0M0. The patients were separated into 4 groups after the operation. Group 1 consisted of 23 patients in whom no additional therapeutic measures were applied in the postoperative period; 8-year survival was 48%. Group 2 was made up of 23 patients who received immunotherapy with the BCG vaccine in the postoperative period; 8-year survival was 60.5%. Group 3 consisted of 9 patients who were given levamisole for immunotherapy in the postoperative period; 8-year survival was 44%. Group 4 consisted of 8 patients who were treated by a combined method in the postoperative period: administration of the BCG vaccine, a placental suspension, and cyclophosphamide; 8-year survival was 75%. Multiple metastases occurred in 26 patients. Nineteen patients did not receive additional treatment in the postoperative period; 2 patients survived for 1 year, none of the patients lived longer than 2 years. Seven patients were given immunotherapy with the BCG vaccine in the postoperative period; 6 patients survived 1 year, 4 patients--2 years. Measures for increasing the activity of the immune and macrophagal systems should be included in the schedule of complex treatment for patients with carcinoma of the kidney.